Genmab A/S (NASDAQ:GMAB) Shares Gap Down – Time to Sell?

Genmab A/S (NASDAQ:GMAB) gapped down before the market opened on Monday . The stock had previously closed at $19.76, but opened at $19.01. Genmab A/S shares last traded at $19.09, with a volume of 178,264 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on GMAB shares. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a report on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $41.33.

Genmab A/S Price Performance

The firm has a market capitalization of $12.72 billion, a P/E ratio of 11.05, a P/E/G ratio of 2.65 and a beta of 0.98. The company’s 50-day simple moving average is $21.04 and its two-hundred day simple moving average is $22.12.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently modified their holdings of GMAB. China Universal Asset Management Co. Ltd. grew its stake in Genmab A/S by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock valued at $186,000 after acquiring an additional 827 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC grew its stake in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after buying an additional 950 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares during the last quarter. Finally, Eagle Asset Management Inc. lifted its holdings in shares of Genmab A/S by 10.0% in the 3rd quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock worth $285,000 after acquiring an additional 1,121 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.